Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Next Previous
Trial Profile

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GV20-0251 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Carcinoma; Colon cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Rectal cancer; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-F77
  • Sponsors GV20 Oncotherapy; Merck Sharp & Dohme

Most Recent Events

  • 02 Jun 2025 Results presented in the GV20 Oncotherapy Media Release.
  • 02 Jun 2025 According to GV20 Oncotherapy media release, company presented updated clinical from this study at the American Society of Clinical Oncology 2025 Annual Meeting.
  • 23 May 2025 According to GV20 Oncotherapy media release, company will present updated clinical and translational data of GV20-0251 monotherapy at the American Society of Clinical Oncology 2025 Annual Meeting, taking place in Chicago, IL on May 30- June 3, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top